TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
PolyPeptide Laboratories (Sweden) AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
1,216,299
|
1,080,164
|
852,574 |
| Financial expenses |
15,063
|
23,781
|
3,480 |
| Earnings before taxes |
333,334
|
196,418
|
283,427 |
| EBITDA |
377,843
|
262,149
|
263,524 |
| Total assets |
2,724,830
|
2,017,299
|
1,434,993 |
| Current assets |
1,756,622
|
1,342,478
|
846,887 |
| Current liabilities |
621,623
|
422,634
|
297,763 |
| Equity capital |
905,358
|
1,133,990
|
989,880 |
| - share capital |
11,860
|
11,650
|
10,878 |
| Employees (average) |
350
|
312
|
325 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
33.2%
|
56.2%
|
69.0% |
| Turnover per employee |
3,475
|
3,462
|
2,623 |
| Profit as a percentage of turnover |
27.4%
|
18.2%
|
33.2% |
| Return on assets (ROA) |
12.8%
|
10.9%
|
20.0% |
| Current ratio |
282.6%
|
317.6%
|
284.4% |
| Return on equity (ROE) |
36.8%
|
17.3%
|
28.6% |
| Change turnover |
116,658
|
167,095
|
-71,762 |
| Change turnover % |
11%
|
18%
|
-8% |
| Chg. No. of employees |
38
|
-13
|
28 |
| Chg. No. of employees % |
12%
|
-4%
|
9% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.